BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 31204938)

  • 21. EZH2 induces the expression of miR-1301 as a negative feedback control mechanism in triple negative breast cancer.
    Wu Q; Chen Z; Zhang G; Zhou W; Peng Y; Liu R; Chen C; Feng J
    Acta Biochim Biophys Sin (Shanghai); 2018 Jul; 50(7):693-700. PubMed ID: 29790898
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MiR-124 induces autophagy-related cell death in cholangiocarcinoma cells through direct targeting of the EZH2-STAT3 signaling axis.
    Ma J; Weng L; Wang Z; Jia Y; Liu B; Wu S; Cao Y; Sun X; Yin X; Shang M; Mao A
    Exp Cell Res; 2018 May; 366(2):103-113. PubMed ID: 29530475
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Expression and Clinical Significance of MiR-215 and KDM1B in Patients with Diffuse Large B Cell Lymphoma].
    Wu RJ; Zou Y; Ma XD; Zheng RJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Oct; 28(5):1570-1577. PubMed ID: 33067956
    [TBL] [Abstract][Full Text] [Related]  

  • 24. miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator.
    Husby S; Ralfkiaer U; Garde C; Zandi R; Ek S; Kolstad A; Jerkeman M; Laurell A; Räty R; Pedersen LB; Pedersen A; Ehinger M; Sundström C; Karjalainen-Lindsberg ML; Delabie J; Clasen-Linde E; Brown P; Cowland JB; Workman CT; Geisler CH; Grønbæk K
    Blood; 2015 Apr; 125(17):2669-77. PubMed ID: 25736311
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MicroRNA signature obtained from the comparison of aggressive with indolent non-Hodgkin lymphomas: potential prognostic value in mantle-cell lymphoma.
    Goswami RS; Atenafu EG; Xuan Y; Waldron L; Reis PP; Sun T; Datti A; Xu W; Kuruvilla J; Good DJ; Lai R; Church AJ; Lam WS; Baetz T; Lebrun DP; Sehn LH; Farinha P; Jurisica I; Bailey DJ; Gascoyne RD; Crump M; Kamel-Reid S
    J Clin Oncol; 2013 Aug; 31(23):2903-11. PubMed ID: 23835716
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MiR-137 suppresses migration and invasion by targeting EZH2-STAT3 signaling in human hepatocellular carcinoma.
    Huang B; Huang M; Li Q
    Pathol Res Pract; 2018 Dec; 214(12):1980-1986. PubMed ID: 30274685
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TUG1 promotes osteosarcoma tumorigenesis by upregulating EZH2 expression via miR-144-3p.
    Cao J; Han X; Qi X; Jin X; Li X
    Int J Oncol; 2017 Oct; 51(4):1115-1123. PubMed ID: 28902349
    [TBL] [Abstract][Full Text] [Related]  

  • 28. miR-223 is repressed and correlates with inferior clinical features in mantle cell lymphoma through targeting SOX11.
    Zhou K; Feng X; Wang Y; Liu Y; Tian L; Zuo W; Yi S; Wei X; Song Y; Qiu L
    Exp Hematol; 2018 Feb; 58():27-34.e1. PubMed ID: 29158064
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MiR-26a and miR-138 block the G1/S transition by targeting the cell cycle regulating network in prostate cancer cells.
    Erdmann K; Kaulke K; Rieger C; Salomo K; Wirth MP; Fuessel S
    J Cancer Res Clin Oncol; 2016 Nov; 142(11):2249-61. PubMed ID: 27562865
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Distinct BTK inhibitors differentially induce apoptosis but similarly suppress chemotaxis and lipid accumulation in mantle cell lymphoma.
    Liu Z; Liu J; Zhang T; Li L; Zhang S; Jia H; Xia Y; Shi M; Zhang J; Yue S; Chen X; Yu J
    BMC Cancer; 2021 Jun; 21(1):732. PubMed ID: 34174847
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Lncrna-TUG1/EZH2 Axis Promotes Pancreatic Cancer Cell Proliferation, Migration and EMT Phenotype Formation Through Sponging Mir-382.
    Zhao L; Sun H; Kong H; Chen Z; Chen B; Zhou M
    Cell Physiol Biochem; 2017; 42(6):2145-2158. PubMed ID: 28813705
    [TBL] [Abstract][Full Text] [Related]  

  • 32. miR-101a targeting EZH2 promotes the differentiation of goat skeletal muscle satellite cells.
    Li JT; Zhao W; Li DD; Feng J; Ba G; Song TZ; Zhang HP
    Yi Chuan; 2017 Sep; 39(9):828-836. PubMed ID: 28936980
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EZH2 promotes hepatocellular carcinoma progression through modulating miR-22/galectin-9 axis.
    Chen S; Pu J; Bai J; Yin Y; Wu K; Wang J; Shuai X; Gao J; Tao K; Wang G; Li H
    J Exp Clin Cancer Res; 2018 Jan; 37(1):3. PubMed ID: 29316949
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MicroRNA-4465 suppresses tumor proliferation and metastasis in non-small cell lung cancer by directly targeting the oncogene EZH2.
    Sun J; Tian X; Lu SQ; Hu HB
    Biomed Pharmacother; 2017 Dec; 96():1358-1362. PubMed ID: 29169732
    [TBL] [Abstract][Full Text] [Related]  

  • 35. miR-101 suppresses tumor proliferation and migration, and induces apoptosis by targeting EZH2 in esophageal cancer cells.
    Lin C; Huang F; Li QZ; Zhang YJ
    Int J Clin Exp Pathol; 2014; 7(10):6543-50. PubMed ID: 25400732
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MicroRNA-144 suppresses tumorigenesis and tumor progression of astrocytoma by targeting EZH2.
    Lin L; Zheng Y; Tu Y; Wang Z; Liu H; Lu X; Xu L; Yuan J
    Hum Pathol; 2015 Jul; 46(7):971-80. PubMed ID: 25907866
    [TBL] [Abstract][Full Text] [Related]  

  • 37. LncRNA MALAT1 promotes colorectal cancer development by sponging miR-363-3p to regulate EZH2 expression.
    Xie JJ; Li WH; Li X; Ye W; Shao CF
    J Biol Regul Homeost Agents; 2019; 33(2):331-343. PubMed ID: 30972996
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MiR-340 impedes the progression of laryngeal squamous cell carcinoma by targeting EZH2.
    Yu W; Zhang G; Lu B; Li J; Wu Z; Ma H; Wang H; Lian R
    Gene; 2016 Feb; 577(2):193-201. PubMed ID: 26656176
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of Enhancer of Zeste Homolog 2 (EZH2) Expression on Brain Glioma Cell Proliferation and Tumorigenesis.
    Cheng T; Xu Y
    Med Sci Monit; 2018 Oct; 24():7249-7255. PubMed ID: 30305602
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hsa_circ_0071589 promotes carcinogenesis via the miR-600/EZH2 axis in colorectal cancer.
    Yong W; Zhuoqi X; Baocheng W; Dongsheng Z; Chuan Z; Yueming S
    Biomed Pharmacother; 2018 Jun; 102():1188-1194. PubMed ID: 29710537
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.